This is a working overview of immunomodulator, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The first atomic bomb test, codenamed "Trinity "and detonated on July 16, 1945, near Alamogordo, New Mexico, used plutonium as its fissile material. The implosion design of "Gadget", as the Trinity device was codenamed, used conventional explosive lenses to compress a sphere of plutonium into a supercritical mass, which was simultaneously showered with neutrons from "Urchin", an initiator made of polonium and beryllium (neutron source: (α, n) reaction). Together, these ensured a runaway chain reaction and explosion. The weapon weighed over 4 tonnes, though it had just 6 kg of plutonium. About 20% of the plutonium in the Trinity weapon, fissioned; releasing an energy equivalent to about 20,000 tons of TNT. An identical design was used in "Fat Man", dropped on Nagasaki, Japan, on August 9, 1945, killing 35,000–40,000 people and destroying 68%–80% of war production at Nagasaki. Only after the announcement of the first atomic bombs was the existence and name of plutonium made known to the public by the Manhattan Project's Smyth Report.
ECL cells synthesize and secrete histamine. These cells are stimulated by the hormones gastrin (not depicted in the adjacent diagram) and pituitary adenylyl cyclase-activating peptide. G cells are stimulated by vagal stimulation through the neurotransmitter gastrin-releasing peptide; this causes the G cells to secrete gastrin, which in turn stimulates ECL cells to release histamine. Note that this circuit is not activated by acetylcholine (ACh), which is of particular importance because the administration of atropine will not block the vagal stimulation of the G cells, as ACh is not the neurotransmitter for these cells. However, ECL cells are activated directly by ACh on M1 receptors from direct vagal innervation leading to histamine release. This pathway will be inhibited by atropine. Gastrin is transferred from a specific type of G cell in the gastric epithelium to the ECL cells by blood. Histamine and gastrin act synergistically as the most important stimulators of hydrochloric acid secretion from parietal cells and stimulators of secretion of pepsinogen from chief cells. The most important inhibitor of the ECL cell is somatostatin from D cells. Enterochromaffin-like cells also produce pancreastatin and probably other peptide hormones and growth factors.
==== Joining the Colorado Party ==== Peña joined the conservative Colorado Party on 29 October 2016, having previously been a member of the Authentic Radical Liberal Party (PLRA) for 20 years since joining at the age of 17. Peña's membership in the Colorado Party caused controversy, with reports that he only joined the party after Horacio Cartes announced his intention to dismiss members of his cabinet who were not party members. Peña released a statement stating he had joined the party due to its focus on developing Paraguay, and claimed to be the descendent of one of the party's founders, Jaime Peña. Following this, an electoral court annulled Peña's membership to the PLRA.
As such, Hamilton argues that the focus of this teaching is on our subjective experience, not on anything external to it. Collett Cox also sees the theory of dependent origination found in the early Buddhist sources as an analysis of how suffering is produced in our experience. Cox states that it is only in later Abhidharma literature that dependent origination became an abstract theory of causation. A similar interpretation has been put forth by Bhikkhu Buddhadasa who argues that, in the list of the twelve nidanas, jati and jaramarana refer not to rebirth and physical death, but to the birth and death of our self-concept, the "emergence of the ego". According to Buddhadhasa,
Sources: en.wikipedia.org
In physics and chemistry, binding energy is the smallest amount of energy required to remove a particle from a system of particles or to disassemble a system of particles into individual parts. In the former meaning the term is predominantly used in condensed matter physics, atomic physics, and chemistry, whereas in nuclear physics the term separation energy is used. A bound system is typically at a lower energy level than its unbound constituents. According to relativity theory, a ΔE decrease in the total energy of a system is accompanied by a decrease Δm in the total mass, where Δmc2 = ΔE. There are several types of binding energy, each operating over a different distance and energy scale. The smaller the size of a bound system, the higher its associated binding energy.
== Sodium-23 == Sodium-23 is the sole natural isotope of sodium, with an atomic mass of 22.98976928. Because of this, sodium-23 is used in nuclear magnetic resonance in various research fields, including materials science and battery research. Sodium-23 relaxation has applications in studying cation-biomolecule interactions, intracellular and extracellular sodium, ion transport in batteries, and quantum information processing.
=== A10AB Insulins and analogues for injection, fast-acting === A10AB01 Insulin (human) A10AB02 Insulin (beef) A10AB03 Insulin (pork) A10AB04 Insulin lispro A10AB05 Insulin aspart A10AB06 Insulin glulisine A10AB30 Combinations
=== 2010-2013 === A book A Little War That Shook the World by Ronald Asmus was published in January 2010. One staff worker for Dick Cheney is quoted as expressing concern that American president George W. Bush had probably given Putin a "green light" to start hostilities against Georgia during the April 2008 meeting in Sochi. The book reported that French president Sarkozy said that he was ready to confront Russia on Georgia's NATO membership, but not German Chancellor Merkel. Germany's refusal to submit to the US proposal was a first time the US interests were neglected in the NATO and Putin used NATO's hesitation as an opportunity to wage the war against its neighbor. Asmus stated: "Many in the West tried to step back and pretend that the Russo-Georgian war was a local conflict they were not a party to." In October 2011, Dmitry Rogozin said in an interview with Echo of Moscow that Russia achieved that Ukraine and Georgia did not become NATO members and Russia gained respect. In 2011, Condoleezza Rice, former Secretary of State, published her memoirs where she wrote that she had told Saakashvili before the war not to respond to Russia because nobody would help him. She told The Weekly Standard that "But in no way were the Georgians at fault..." She said: "They were doing all kinds of things to try to provoke the Georgians. The shelling of Georgian cities by the South Ossetians, Russian allies, is clearly what started the war." Rice also talked about Russian hatred for Georgians.
== History and taxonomy == The fungus was first isolated in 1870 from a tinea cruris patient in Germany by Carl Otto Harz, who named it Acrothecium floccosum. Being unaware of Harz's work, Castellani and Sabouraud identified the species again in 1905 and 1907, respectively, and both placed the fungus into the genus Epidermophyton. Epidermophyton is one of the three dermatophyte fungal genera; it is distinct from the other two genera (Microsporum and Trichophyton) for the absence of microconidia. In 1930, based on the principle of priority, Langeron and Milochevitch renamed the fungus Epidermophyton floccosum to recognize Harz's contribution in identifying the species first, as well as his extensive morphological descriptions. Another fungus, originally named Epidermophyton stockdaleae, is a dark-brown, soil-inhabiting species that is morphologically and molecularly distinct to E. floccosum for its longer conidia and 7% NaCl tolerance. E. stockdaleae is also clinically differentiated from E. floccosum by its ability in perforating hair. Due to the presence of microconidia, E. stockdaleae is now considered a synonym of Trichophyton ajelloi, hence E. floccosum is currently the only species in the genus Epidermophyton.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.